Medifast Inc (MED) Jumps 5.51% on January 11

Equities Staff  |

Medifast Inc (MED) was among the biggest gainers on the Russell 2000 for Monday January 11 as the stock popped 5.51% to $29.48, representing a gain of $1.54 per share. Some 127,280 shares traded hands on 1,368 trades, compared with an average daily volume of 108,175 shares out of a total float of 11.76 million. The stock opened at $28.80 and traded with an intraday range of $30.23 to $28.77.

After today's gains, Medifast Inc reached a market cap of $346.65 million. Medifast Inc has had a trading range between $33.86 and $26.14 over the last year, and it had a 50-day SMA of $29.97 and a 200-day SMA of $29.92.

The stock has a P/E Ratio of 25.6.

Medifast Inc is engaged in the productions, distributions, and sales of weight loss and weight management products and other consumable health and diet products. Its product lines include weight loss and management, meal replacement, and vitamins.

Medifast Inc is based out of Owings Mills, MD and has some 579 employees. Its CEO is Michael C. Macdonald.

For a complete fundamental analysis analysis of Medifast Inc, check out’s Stock Valuation Analysis report for MED. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.